BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23447478)

  • 1. Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study.
    Russo PA; Wiese MD; Smith MD; Ahern MJ; Barbara JA; Shanahan EM
    Ann Pharmacother; 2013 Mar; 47(3):e15. PubMed ID: 23447478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.
    Bergner R; Peters L; Schmitt V; Löffler C
    Clin Rheumatol; 2013 Feb; 32(2):267-70. PubMed ID: 23179005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hemodialysis on leflunomide plasma concentrations.
    Beaman JM; Hackett LP; Luxton G; Illett KF
    Ann Pharmacother; 2002 Jan; 36(1):75-7. PubMed ID: 11816264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
    Bohanec Grabar P; Grabnar I; Rozman B; Logar D; Tomsic M; Suput D; Trdan T; Peterlin Masic L; Mrhar A; Dolzan V
    Drug Metab Dispos; 2009 Oct; 37(10):2061-8. PubMed ID: 19581389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.
    Wiese MD; Schnabl M; O'Doherty C; Spargo LD; Sorich MJ; Cleland LG; Proudman SM
    Arthritis Res Ther; 2012 Jul; 14(4):R163. PubMed ID: 22784880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.
    Soukup T; Dosedel M; Nekvindova J; Toms J; Vlcek J; Pavek P
    Clin Exp Rheumatol; 2015; 33(3):426-32. PubMed ID: 25664505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.
    Bae J; Park JW
    Drug Dev Ind Pharm; 2016; 42(2):254-62. PubMed ID: 26006334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide.
    Makarem YS; Hareedy MS; Hassanien M; Ahmed EA; Hetta HF; Mohamed AA
    Pharmacogenomics; 2021 Dec; 22(18):1201-1209. PubMed ID: 34747629
    [No Abstract]   [Full Text] [Related]  

  • 9. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
    Flendrie M; Creemers MC; Welsing PM; van Riel PL
    Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
    Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
    Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level.
    Kim KA; Joo HJ; Park JY
    Eur J Clin Pharmacol; 2011 Feb; 67(2):129-34. PubMed ID: 20972558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects.
    Yao X; Wu Y; Jiang J; Hu P; Liu D; Chen X
    Clin Drug Investig; 2019 Jul; 39(7):643-651. PubMed ID: 31016613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity.
    Ma LL; Wu ZT; Wang L; Zhang XF; Wang J; Chen C; Ni X; Lin YF; Cao YY; Luan Y; Pan GY
    Acta Pharmacol Sin; 2016 Mar; 37(3):415-24. PubMed ID: 26806301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
    Kalden JR; Scott DL; Smolen JS; Schattenkirchner M; Rozman B; Williams BD; Kvien TK; Jones P; Williams RB; Oed C; Rosenburg R;
    J Rheumatol; 2001 Sep; 28(9):1983-91. PubMed ID: 11550964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of leflunomide.
    Rozman B
    Clin Pharmacokinet; 2002; 41(6):421-30. PubMed ID: 12074690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leflunomide in psoriatic arthritis.
    Kaltwasser JP
    Autoimmun Rev; 2007 Sep; 6(8):511-4. PubMed ID: 17854740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.
    Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Upton RN; Foster DJ
    Br J Clin Pharmacol; 2016 Jan; 81(1):113-23. PubMed ID: 26331989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring of teriflunomide: do plasma concentrations predict response to leflunomide in patients with rheumatoid arthritis?
    Rawdha T; Aicha BT; Lobna BA; Issam S; Mouna BS; Olfa S; Selma B; Takoua BB; Kawther BA; Leila M; Hana S; Ines M; Leila A
    Drug Metab Pers Ther; 2023 Mar; 38(1):79-85. PubMed ID: 35998916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritoneal dialysis is the therapy of choice for end-stage renal disease patients with hereditary clotting disorders.
    Bajo MA; del Peso G; Jiménez V; Aguilera A; Villar A; Jiménez C; Selgas R
    Adv Perit Dial; 2000; 16():170-3. PubMed ID: 11045286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.